There are no projects in the garbage can.
Strategic Line 2: Cancer Genomics
The Functional Genomics area is divided into two strategic lines: the study of the Human Genome and the study of Cancer Genomics, addressing the fundamental mechanisms of genetic and molecular biology.
Home - Functional Genomics Area - Strategic Line 2: Cancer Genomics
Strategic line 2 is called ‘Cancer Genomics’ and encompasses research activity aimed at generating new knowledge to enable the development of new therapeutic approaches to different types of cancer using systems biology methodology such as artificial intelligence.
The activity of the research groups in this strategic line makes GENyO an international benchmark in the knowledge of the molecular bases underlying the development of cancer. GENyO groups contribute to establishing the basic molecular mechanisms underlying the development of different types of cancer, identify new bio-markers useful in clinical practice and contribute to the design of new therapeutic approaches.
Research Groups
Within the line dedicated to Cancer Genomics research, we can find the following associated research groups:
Integration of omics data for the search for molecular biomarkers associated with urological cancers
Dr. Maria Jesús Álvarez
Regulation of Gene Expression in Cancer
Dr. Pedro Medina
Proteases and Extracellular Matrix
Dr. Juan Carlos Rodríguez-Manzaneque
Translational Genomics of Blood Cancers
Dr. Juan Sainz
Epigenetic Memory in Disease
Dr. David Landeira
Strategic Line 1: The Human Genome
The Functional Genomics area is divided into two strategic lines: the study of the Human Genome and the study of Cancer Genomics, addressing the fundamental mechanisms of genetic and molecular biology.
Research
Publications
Variants in the DDX6-CXCR5 autoimmune disease risk locus influence the regulatory network in immune cells and salivary gland.
Authors: Wiley MM, Radziszewski M, Khatri B, Joachims ML, Tessneer KL, Stolarczyk AM, Yao S, Li J, Pritchett-Frazee C, Johnston AA, Rasmussen A, Anaya JM, Aqrawi LA, Bae SC, Baecklund E, Björk A, Brun JG, Bucher SM, Dand N, Eloranta ML, Engelke F, Forsblad-d'Elia H, Fugmann C, Glenn SB, Gong C, Gottenberg JE, Hammenfors D, Imgenberg-Kreuz J, Jensen JL, Johnsen SJA, Jonsson MV, Kelly JA, Khanam S, Kim K, Kvarnström M, Mandl T, Martín J, Morris DL, Nocturne G, Norheim KB, Olsson P, Palm Ø, Pers JO, Rhodus NL, Sjöwall C, Skarstein K, Taylor KE, Tombleson P, Thorlacius GE, Venuturupalli SR, Vital EM, Wallace DJ, Radfar L, Brennan MT, James JA, Scofield RH, Gaffney PM, Criswell LA, Jonsson R, Appel S, Eriksson P, Bowman SJ, Omdal R, Rönnblom L, Warner BM, Rischmueller M, Witte T, Farris AD, Mariette X, Shiboski CH, Sjögren’s International Collaborative Clinical Alliance (SICCA), Wahren-Herlenius M, Alarcón-Riquelme ME, PRECISESADS Clinical Consortium, Ng WF, UK Primary Sjögren’s Syndrome Registry, Sivils KL, Guthridge JM, Adrianto I, Vyse TJ, Tsao BP, Nordmark G, Lessard CJ
05/2025 - Annals of the rheumatic diseases
Machine Learning Analysis of Whole-Blood Transcriptomics Data in Rheumatoid Arthritis Patients Treated with Adalimumab Identifies Predictive Biomarkers of Response.
Authors: Yap CF, Nair N, Morgan AW, Isaacs JD, Wilson AG, Hyrich K, Barturen G, Riva-Torrubia M, Gut M, Gut I, Alarcón Riquelme ME, Barton A, Plant D
05/2025 - Arthritis & rheumatology (Hoboken, N.J.)
Loss of the extracellular protease ADAMTS1 reveals an antitumorigenic program involving the action of NIDOGEN-1 on macrophage polarization.
Authors: Caracuel-Peramos R, Rodríguez-Baena FJ, Redondo-García S, Villatoro-García JA, García-Muñoz A, Peris-Torres C, Plaza-Calonge MDC, Rubio-Gayarre A, López-Millán B, Ricciardelli C, Russell DL, Carmona-Sáez P, Rodríguez-Manzaneque JC
12/2025 - Oncoimmunology
This website uses cookies
We use necessary and optional cookies to provide you with the best possible experience. Click accept to continue or learn more in our cookie policy.
See cookies policy.You have already selected your cookie preferences in previous sessions, do you want to change them?
Mandatory Cookies
They are those that allow the user to navigate through the website, and the use of the different options or services that exist in it as, for example, identify the session, access parts of restricted access, make the purchase process of an order or use security features while browsing.
View the cookies we use.Personalization, analytical or functional cookies
They are those that allow the user to access the service with some general characteristics predefined according to a series of criteria in the user's terminal such as for example would be the language, the type of browser through which you access the service, the locale from which you access the service, quantify the number of users and thus perform the measurement and statistical analysis of the use made by users of the service offered. To do this, your navigation on our website is analyzed in order to improve the supply of products or services that we offer.
View the cookies we use.I accept them:
Advertising or informational cookies
They are those that allow us to manage our information as effectively as possible, adapting its content to user preferences, the type of terminal from which you access the service, the characteristics of the use made by the user of the services, offer own or third-party advertising, etc.. To do this we analyze your browsing habits on the Internet to offer advertising related to the interests of their browsing profiles.
View the cookies we use.I accept them:
Analytical Cookies
They are those that allow us to collect information on the use made of the website.
View the cookies we use.I accept them: